drugset / Trial / NCT00712920

A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies

NCT00712920 ↗

Phase 3 Completed 581 enrolled Meda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine if two allergy medications are more effective than placebo.

Timeline

Start
2007-01
Primary completion
2008-05
Completion
—

Outcome

Met primary endpoint

registry Placebo vs Astepro 0.15%; p = 0.03; Mean Difference (Final Values) -0.90 (95% CI -1.70 to -0.10); ANCOVA NCT00712920 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelastine Small molecule 1096 ug Intranasal
Subject Azelastine Small molecule 1644 ug Intranasal